Adoptive transfer of chimeric FcεRI gene-modified human T cells for cancer immunotherapy

Abstract

Immunotherapeutic approaches involving genetic modification of T cells show promise in generating highly specific tumor-reactive effector cells for cancer treatment. Given the high affinity of FcεRI (the subtype I Fc receptor for IgE) for IgE monoclonal antibody (mAb), modification of T cells with chimeric FcεRI in combination with tumor-specific IgE mAbs is potentially a powerful and effective strategy to specifically target T cells to tumor cells. In this study, we retrovirally transduce human primary T cells with a cDNA encoding the extracellular domain of FcεRI linked to the hinge and transmembrane domains of FcγRII and the cytoplasmic domains of CD28 and T cell receptor ζ chain (Fc εRI-..